eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of EFT508 and Avelumab in Micros
Study conducted in collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer SAN DIEGO, October 4, 2017 – eFFECTOR Therapeutics,...
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of EFT508 and Avelumab in Micros
Vir Biotechnology: Fierce15 Winner
FierceBiotech Names Gritstone Oncology as a "Fierce 15" Biotechnology Company of 2017
BlackThorn Selected as a Fierce15 2017 Winner
AgTech Startup Indigo Is Boston’s Newest Unicorn After $156M Series D
Gritstone Oncology Secures $92.7 Million In Series B Financing
Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
BlackThorn Therapeutics To Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Fundi